Abstract Details

Title Detection of the Presence and Myelination Status of Cortical Lesions Using 7T Magnetization Transfer Imaging in Patients with Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) S51 - (-)

Poster/Presentation
Number 003

Objective

Background Cortical lesions account for a larger proportion of brain demyelination than white matter (WM) lesions. In this study we report for the first time the systematic use of high resolution MTR in MS and compare MTR lesion detection with 7T MPRAGE, 7T T2* and 3T 3D DIR.

Design/Methods Nineteen patients with RRMS and 9 healthy controls were studied. We acquired 7T MPRAGE, 7T MTR, 7T T2* and 3T 3D DIR. The analysis of cortical lesions was blinded through segmentation of the cortex.

Results In the control subjects, 7T T2*, 7T MTR and 7T MPRAGE showed a total of 4, 14 and 12 lesions respectively. In patients with MS 352 lesions in total were detected with 7T MTR (mean 18.5 lesions per patient), 238 lesions were detected with 7T MPRAGE (mean 12.5 lesions) and 52 lesions were detected with 7T T2* (mean 2.7 lesions). In the 9 MS subjects who had 3T DIR, a total of 46 lesions (mean 7.3 lesions per patient) were detected as opposed to 167 lesions with 7T MTR, 124 lesions were detected with 7T MPRAGE and 26 lesions with 7T T2*in the same patients. The percentage reduction of MTR values in the GM lesions was lower than the WM lesions when compared to controls tissues.

Conclusions In this study we have found that 7T MTR was superior in detecting intracortical lesions in comparison to other sequences. MTR was also more sensitive in localizing intracortical lesions. Our preliminary results raised the possibility of increased remyelination in the GM compared to the WM, as it has been reported in pathological studies and offer promise that MTR can be used to quantify GM remyelination in longitudinal studies.

Authors/Disclosures
Rasha Abdel-Fahim PRESENTER	No disclosure on file
Niraj Mistry (University Hospitals Birmingham NHS Foundation Trust)	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Nikolaos Evangelou, PhD (Nottingham University, QMC campus)	Dr. Evangelou has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis . Dr. Evangelou has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis . The institution of Dr. Evangelou has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Roche. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck . Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen . Dr. Evangelou has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for biogen. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for UK crown prosecution service. Dr. Evangelou has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Novartis .
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ)	Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has stock in NeuroRx.

��ɫ��

��ɫ��